Self-funded and founded by WHO and Sweden
UMC's work is governed by an agreement between WHO and the Swedish government. The income we independently generate allows us to sustainably perform our vital role in global pharmacovigilance.
Governance
UMC was founded based on an agreement between WHO and the Swedish government in 1978, and each appoint three members and alternates to the UMC board. The director of UMC reports to the board.
Since May 2019, the board has been chaired by Dr Filippa Nyberg, Senior Consultant at Karolinska University Hospital, and Associate Professor at the Karolinska Institute.
Funding
UMC is self-funded. We finance our operations by providing pharmacovigilance products and services to a range of external bodies, most notably the WHODrug Global portfolio of products. Funding our own operations ensures intellectual and scientific independence, sustainability, and freedom to pursue our vision.
We do not receive other funding from external sources, except in rare instances for specific collaborative projects.